Summary

KEY FINDINGS
The Asia-Pacific dry eye disease market is projected to grow at a CAGR of 5.51% during the forecast period from 2024 to 2032. The market was valued at $1216.91 million in 2023, reaching a revenue of $1987.33 million by 2032.
MARKET INSIGHTS

Factors such as the increasing prevalence of dry eye disease and a rising demand for dry eye disease treatment products are driving the market’s growth across the region. Moreover, a key factor contributing to the growing incidence of dry eye diseases in the Asia-Pacific region is the rapid rise in urbanization and associated lifestyle changes.
REGIONAL ANALYSIS
The Asia-Pacific dry eye disease market growth analysis includes the assessment of Thailand, Indonesia, China, Vietnam, Australia & New Zealand, India, Japan, South Korea, and Rest of Asia-Pacific. Increased exposure to pollution, combined with extensive use of digital devices, is elevating the number of individuals experiencing dry eye disease symptoms such as dryness, irritation, and blurred vision. Furthermore, changes in dietary habits and higher rates of underlying health conditions, such as diabetes, are identified as additional dry eye disease causes.
Japan, a leading country in healthcare innovation, demonstrates a high level of consistency, awareness, and commitment to healthcare improvements. According to two cross-sectional, population-based studies assessing the epidemiology of dry eye disease (DED), Japan had a higher prevalence of DED compared to other countries. Additionally, numerous studies have examined the economic impact of DED, showing that productivity losses per patient with confirmed DED ranged from $741 to $6,160, contributing to a significant economic burden. These factors, along with government support, research and development initiatives, and technological advancements, are expected to drive the demand for dry eye disease treatments in Japan.
In Indonesia, dry eye disease is commonly seen among the elderly, particularly those with cataracts. A study investigating the prevalence and subtypes of DED in the aging population prior to cataract surgery revealed that half of the participants experienced dry eye symptoms, classifying them as either having preclinical dry eye or DED, while over a quarter were identified as being at risk of developing the condition.
The study underscores the prevalence of DED among older adults, who are increasingly susceptible to reduced tear production due to factors such as diminished corneal sensation, altered reflex secretion, lacrimal gland dysfunction, or inflammation-related damage to lacrimal glands. Furthermore, the role of oxidative stress and inflammation, which escalate with aging, is significant in the development of dry eye in the elderly. As a result, these factors are set to shape the landscape of the dry eye disease market in Indonesia.
The growing geriatric population in countries like Japan and South Korea is another significant driver of the market, as older individuals are more susceptible to age-related eye conditions. This, combined with an overall rise in healthcare awareness and access to diagnostic services, is boosting the market for treatment for dry eye disease across the region.
Innovations in dry eye disease treatment drugs and products are playing a crucial role in managing the condition. New therapies, such as eye drops for dry eye disease, as well as advancements in anti-inflammatory medications, are addressing patient needs more effectively. In addition, technological advancements in therapeutic and diagnostic products are enabling earlier and more accurate dry eye disease diagnosis, which is expected to drive treatment adoption across various markets in the region.
SEGMENTATION ANALYSIS
The Asia-Pacific dry eye disease market segmentation includes distribution channel, type, dosage, and product. The distribution channel segment is further divided into hospital pharmacies, online pharmacies/stores, and independent pharmacies and drugstores.
Online pharmacies have become a well-established distribution channel, gradually gaining acceptance in emerging markets while being thoroughly utilized in developed countries. The demand for a wide range of products available online has surged, driven by increased internet penetration. Consequently, the expansion of online services, the trend towards self-medication with over-the-counter products, and the growing use of the Internet have significantly boosted sales through online pharmacies. Additionally, rising awareness of primary care and prescription medications is expected to further drive growth in this segment.
Moreover, as healthcare technology advances, virtual healthcare is becoming increasingly popular, prompting pharmacies to enhance their online services. Most medications for dry eye disease are available as eye drops, which can conveniently be purchased online. Furthermore, during the pandemic, many consumers preferred using online pharmacies over visiting crowded physical stores, accelerating the shift towards digital pharmacy solutions.
COMPETITIVE INSIGHTS
Some of the leading companies operating in the Asia-Pacific dry eye disease market include Santen Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Sentiss Pharma Private Limited, etc.
Santen Pharmaceutical Co Ltd specializes in the marketing, manufacturing, and research & development of pharmaceutical products and medical devices. The company operates through its network of subsidiaries across the United States, Europe, and Asia. Its product portfolio includes prescription ophthalmic solutions for conditions such as glaucoma, diabetic retinopathy, myopia, dry eye, cataracts, and retinal detachment. Headquartered in Kita-ku, Osaka, Japan, Santen is a leading player in the ophthalmic sector. One of its notable products, IKERVIS®, is a treatment for severe keratitis in adults and contains the active ingredient ciclosporin.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE
2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE
2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS
2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS
3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE
3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS
3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC DRY EYE DISEASE MARKET
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DOSAGE
7.1. EYE DROPS
7.2. EYE SOLUTIONS
7.3. OINTMENTS
7.4. GELS
7.5. CAPSULES & TABLETS
8. MARKET BY DISTRIBUTION CHANNEL
8.1. HOSPITAL PHARMACIES
8.2. INDEPENDENT PHARMACIES AND DRUG STORES
8.3. ONLINE PHARMACIES/STORES
9. GEOGRAPHICAL ANALYSIS
9.1. ASIA-PACIFIC
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
9.1.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
9.1.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
9.1.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
9.1.6. COUNTRY ANALYSIS
9.1.6.1. CHINA
9.1.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.2. JAPAN
9.1.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.3. INDIA
9.1.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.4. SOUTH KOREA
9.1.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.5. THAILAND
9.1.6.5.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.6. VIETNAM
9.1.6.6.1. VIETNAM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.7. INDONESIA
9.1.6.7.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.8. AUSTRALIA & NEW ZEALAND
9.1.6.8.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.9. REST OF ASIA-PACIFIC
9.1.6.9.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. ALCON
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCT LIST
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCT LIST
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. BAUSCH HEALTH COMPANIES INC
10.2.3.1. COMPANY OVERVIEW
10.2.3.2. PRODUCT LIST
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. JOHNSON & JOHNSON
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCT LIST
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. AFT PHARMACEUTICALS
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCT LIST
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. LUMENIS
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCT LIST
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. NOVALIQ GMBH
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCT LIST
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. OASIS MEDICAL
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCTS LIST
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. OTSUKA PHARMACEUTICAL CO LTD
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCT LIST
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. SANTEN PHARMACEUTICAL CO LTD
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCTS LIST
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. NOVARTIS AG
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCT LIST
10.2.11.3. STRENGTHS & CHALLENGES
10.2.12. SENTISS PHARMA PRIVATE LIMITED
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCTS LIST
10.2.12.3. STRENGTHS & CHALLENGES
10.2.13. TEVA PHARMACEUTICAL INDUSTRIES LTD
10.2.13.1. COMPANY OVERVIEW
10.2.13.2. PRODUCT LIST
10.2.13.3. STRENGTHS & CHALLENGES
10.2.14. SUN PHARMACEUTICAL INDUSTRIES LTD
10.2.14.1. COMPANY OVERVIEW
10.2.14.2. PRODUCT LIST
10.2.14.3. STRENGTHS & CHALLENGES
10.2.15. VISUFARMA
10.2.15.1. COMPANY OVERVIEW
10.2.15.2. PRODUCT LIST
10.2.15.3. STRENGTHS & CHALLENGES